Bristol Myers Squibb Company $BMY Stake Boosted by Achmea Investment Management B.V.

Achmea Investment Management B.V. grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 16.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,009,890 shares of the biopharmaceutical company’s stock after purchasing an additional 140,840 shares during the quarter. Achmea Investment Management B.V.’s holdings in Bristol Myers Squibb were worth $45,547,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in BMY. Brighton Jones LLC grew its stake in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares during the last quarter. United Bank boosted its holdings in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares during the period. Citizens Financial Group Inc. RI grew its position in shares of Bristol Myers Squibb by 25.1% during the second quarter. Citizens Financial Group Inc. RI now owns 44,213 shares of the biopharmaceutical company’s stock worth $2,047,000 after acquiring an additional 8,876 shares during the last quarter. Finally, Western Wealth Management LLC grew its position in shares of Bristol Myers Squibb by 14.8% during the second quarter. Western Wealth Management LLC now owns 22,673 shares of the biopharmaceutical company’s stock worth $1,050,000 after acquiring an additional 2,923 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $59.71 on Wednesday. The company has a market cap of $121.59 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 0.17 and a beta of 0.26. The business has a 50 day moving average price of $58.47 and a 200 day moving average price of $51.64. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: HSBC raised its price target on BMY from $53 to $60 and kept a “hold” rating, signaling improved near-term analyst sentiment (though the new PT offers only ~0.5% upside from current levels). Benzinga
• Positive Sentiment: BMY reported that its investigational candidate BMS-986278 advanced through a key heart safety study (Phase 1 update), reducing development risk for that program and supporting pipeline value upside if subsequent data are favorable. TipRanks: BMS-986278 Update
• Neutral Sentiment: Zacks published a piece framing BMY as a strong value stock based on style scores and valuation metrics — a reminder that some investors are viewing BMY as a defensive, income-oriented pick rather than a high-growth biotech. Zacks: Value Stock
• Neutral Sentiment: Recent market commentary notes BMY has slightly outperformed recent market returns, reflecting stability from its commercial portfolio and dividend profile rather than fresh catalysts. Yahoo Finance: Market Performance
• Neutral Sentiment: Analyst comparisons (Pfizer vs. BMY) highlight competition in oncology and pipeline-driven M&A/portfolio moves; these comparisons keep investor focus on relative pipeline strength and strategic deals. Zacks: PFE vs BMY

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. HSBC raised their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Royal Bank Of Canada began coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price on the stock. Finally, Citigroup increased their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $61.41.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.